Galectin Therapeutics Inc. (GALT: Quote) Friday reported second quarter net loss to common shares of $3.0 million or $0.19 per share, compared with a net loss of $3.9 million or $0.34 per share last year.
Research and development expense for the quarter was $1.2 million, compared with $1.3 million a year ago. Other expenses decreased to $1.5 million from $1.7 million in the prior year.
The company did not record any revenues for the quarter, as in the prior year.
Click here to receive FREE breaking news email alerts for GALECTIN THERAPEUTICS INC and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com